当前位置:首页>SCI TOP 10


Westborg, I., Albrecht, S., Rosso, A.




摘要:目的:旨在探讨日常临床实践中,雷珠单抗或贝伐珠单抗治疗新生血管性年龄相关性黄斑变性患者的疗效。方法:报告了2011 - 2014年间瑞典黄斑注册的3,912例治疗患者数据。讨论首次就诊时患者的特征,视力,注射次数和终止治疗的理由。此外,计算1年和2年后治疗眼视力不良风险(60个早期治疗糖尿病视网膜病研究字母或约20/60 Snellen以下视力)。结果:治疗预后取决于首次就诊视力。对于视力超过60个字母的患者,1年或2年后治疗眼视力低于60个字母的风险约为20%。但是,对于诊断时低视力患者(少于60个字母),风险约为60%。视力低于60个字母的风险不取决于治疗药物的选择。结论:抗血管内皮生长因子玻璃体腔内注射治疗主要保持视力水平,只有约20%和40%患者分别在1年和2年后需要视力康复。

PURPOSE:To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice.METHODS:Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years.RESULTS:The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug.CONCLUSION:Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.


CopyRight 2016  兴齐100版权所有 京ICP证060955号